{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:04:14Z","timestamp":1776405854373,"version":"3.51.2"},"reference-count":37,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PRA"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>As the second most prevalent hematologic malignancy, multiple myeloma\n(MM) affects plasma cells and is characterized by chromosomal abnormalities, particularly\ninvolving the immunoglobulin heavy chain switch region. MM represents a biologically and clinically\nheterogeneous hematological malignancy that serves as a clonal evolution model, exhibiting\nclonal heterogeneity throughout all stages from monoclonal gammopathy undetermined significance\n(MGUS) and smoldering multiple myeloma (SMM) to MM. Although significant progress\nhas been made in the treatment of MM, leading to improved patient outcomes, concerns are arising\nregarding disease relapse due to the presence and selection of pre-existing resistant clones or\nselective pressure during therapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Case Presentation:<\/jats:title>\n<jats:p>We present a case of multiple myeloma (MM) in a female patient, who underwent\nan 8-year course of treatment, including chemotherapy, immunomodulators, hematopoietic\nstem cell transplantation, CD38 monoclonal antibody, and chimeric antigen receptor T-cell\n(CAR-T), and was recently diagnosed with concurrent progressive MM and acute myeloid leukemia\n(AML). This patient has witnessed the evolution of MM treatment paradigms.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>In this course, disease relapses occurred twice, one of which was manifested by a\nlight chain escape (LCE). Moreover, through the course of the disease in this patient, we review\nthe process of clonal evolution that may be relevant.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574892818666230619093300","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T06:36:55Z","timestamp":1687329415000},"page":"396-401","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a\n61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy"],"prefix":"10.2174","volume":"19","author":[{"given":"Xue-Hang","family":"Fu","sequence":"first","affiliation":[{"name":"Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Yan","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aviation General Hospital, Beijing, 100012, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoufang","family":"Huang","sequence":"additional","affiliation":[{"name":"Ganzhou Key Laboratory of Hematology, Department of Hematology, The First Affiliated Hospital of Gannan Medical University, 341000 Ganzhou, Jiangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aviation General Hospital, Beijing, 100012, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shengli Oilfield Central Hospital, Dongying, 257099, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Wei","family":"Mou","sequence":"additional","affiliation":[{"name":"Department\nof Pediatrics, Shengli Oilfield Central Hospital, Dongying, 257034, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"Rajkumar S.V.","year":"2014","unstructured":"Rajkumar S.V.; Dimopoulos M.A.; Palumbo A.; International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014,15(12),e538-e548","journal-title":"Lancet Oncol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"5949","DOI":"10.3390\/cancers13235949","volume":"13","author":"Aksenova A.Y.","year":"2021","unstructured":"Aksenova A.Y.; Zhuk A.S.; Lada A.G.; Genome instability in multiple myeloma: facts and factors. Cancers 2021,13(23),5949","journal-title":"Cancers"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","volume":"14","author":"Manier S.","year":"2017","unstructured":"Manier S.; Salem K.Z.; Park J.; Landau D.A.; Getz G.; Ghobrial I.M.; Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol 2017,14(2),100-113","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3390\/diagnostics11091534","volume":"11","author":"Salomon-Perzy\u0144ski A.","year":"2021","unstructured":"Salomon-Perzy\u0144ski A.; Jamroziak K.; G\u0142odkowska-Mr\u00f3wka E.; Clonal evolution of multiple myeloma-clinical and diagnostic implications. Diagnostics 2021,11(9),1534","journal-title":"Diagnostics"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ccell.2015.10.014","volume":"28","author":"Braggio E.","year":"2015","unstructured":"Braggio E.; Kort\u00fcm K.M.; Stewart A.K.; Snapshot: multiple myeloma. Cancer Cell 2015,28(5),678-678.e1","journal-title":"Cancer Cell"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.3390\/cancers13102465","volume":"13","author":"Schjesvold F.","year":"2021","unstructured":"Schjesvold F.; Oriol A.; Current and novel alkylators in multiple myeloma. Cancers 2021,13(10),2465","journal-title":"Cancers"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00277-018-3465-8","volume":"98","author":"Burwick N.","year":"2019","unstructured":"Burwick N.; Sharma S.; Glucocorticoids in multiple myeloma: past, present, and future. Ann Hematol 2019,98(1),19-28","journal-title":"Ann Hematol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.bbmt.2019.11.018","volume":"26","author":"Giralt S.","year":"2020","unstructured":"Giralt S.; Costa L.J.; Maloney D.; Tandem autologous-autologous versus autologous-allogeneic hematopoietic stem cell transplant for patients with multiple myeloma: long-term follow-up results from the blood and marrow transplant clinical trials network 0102 trial. Biol Blood Marrow Transplant 2020,26(4),798-804","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/cancers12020265","volume":"12","author":"Ito S.","year":"2020","unstructured":"Ito S.; Proteasome inhibitors for the treatment of multiple myeloma. Cancers 2020,12(2),265","journal-title":"Cancers"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","volume":"77","author":"Holstein S.A.","year":"2017","unstructured":"Holstein S.A.; McCarthy P.L.; Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs 2017,77(5),505-520","journal-title":"Drugs"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4049\/jimmunol.1501351","volume":"197","author":"Overdijk M.B.","year":"2016","unstructured":"Overdijk M.B.; Jansen J.H.M.; Nederend M.; The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via fc\u03b3 receptor-mediated cross-linking. J Immunol 2016,197(3),807-813","journal-title":"J Immunol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/cts.12532","volume":"11","author":"Ritchie D.","year":"2018","unstructured":"Ritchie D.; Colonna M.; Mechanisms of action and clinical development of elotuzumab. Clin Transl Sci 2018,11(3),261-266","journal-title":"Clin Transl Sci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"m3176","DOI":"10.1136\/bmj.m3176","volume":"370","author":"Shah U.A.","year":"2020","unstructured":"Shah U.A.; Mailankody S.; Emerging immunotherapies in multiple myeloma. BMJ 2020,370,m3176","journal-title":"BMJ"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1182\/blood-2019-129431","volume":"134","author":"Spencer A.","year":"2019","unstructured":"Spencer A.; Mollee P.; Blacklock H.A.; Real-world outcome for newly diagnosed patients with functional high-risk myeloma - a myeloma and related diseases registry analysis. Blood 2019,134(Suppl. 1),269-9","journal-title":"Blood"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"van de Donk N.W.C.J.","year":"2021","unstructured":"van de Donk N.W.C.J.; Pawlyn C.; Yong K.L.; Multiple myeloma. Lancet 2021,397(10272),410-427","journal-title":"Lancet"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/annonc\/mdw606","volume":"28","author":"Musto P.","year":"2017","unstructured":"Musto P.; Anderson K.C.; Attal M.; Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol 2017,28(2),228-245","journal-title":"Ann Oncol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1056\/NEJMc1111010","volume":"365","author":"Landgren O.","year":"2011","unstructured":"Landgren O.; Thomas A.; Mailankody S.; Myeloma and second primary cancers. N Engl J Med 2011,365(23),2241-2242","journal-title":"N Engl J Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1034\/j.1600-0609.2000.90218.x","volume":"65","year":"2000","unstructured":"Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study. Eur J Haematol 2000,65(2),123-127","journal-title":"Eur J Haematol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41408-020-00400-4","volume":"11","author":"Rosenberg A.S.","year":"2021","unstructured":"Rosenberg A.S.; Brunson A.; Tuscano J.; Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. Blood Cancer J 2021,11(1),5","journal-title":"Blood Cancer J"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"McCarthy P.L.","year":"2017","unstructured":"McCarthy P.L.; Holstein S.A.; Petrucci M.T.; Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol 2017,35(29),3279-3289","journal-title":"J Clin Oncol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/2040620718775629","volume":"9","author":"Holstein S.A.","year":"2018","unstructured":"Holstein S.A.; Suman V.J.; McCarthy P.L.; Update on the role of lenalidomide in patients with multiple myeloma. Ther Adv Hematol 2018,9(7),175-190","journal-title":"Ther Adv Hematol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"Attal M.","year":"2012","unstructured":"Attal M.; Lauwers-Cances V.; Marit G.; Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012,366(19),1782-1791","journal-title":"N Engl J Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1182\/blood-2012-04-421883","volume":"120","author":"Usmani S.Z.","year":"2012","unstructured":"Usmani S.Z.; Sexton R.; Hoering A.; Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood 2012,120(8),1597-1600","journal-title":"Blood"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1365-2141.2011.08905.x","volume":"156","author":"Fenk R.","year":"2012","unstructured":"Fenk R.; Neubauer F.; Bruns I.; Secondary primary malignancies in patients with multiple myeloma treated with high-dose chemotherapy and autologous blood stem cell transplantation. Br J Haematol 2012,156(5),683-686","journal-title":"Br J Haematol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","volume":"31","author":"San Miguel J.F.","year":"2013","unstructured":"San Miguel J.F.; Schlag R.; Khuageva N.K.; Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 2013,31(4),448-455","journal-title":"J Clin Oncol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"Dimopoulos M.A.","year":"2016","unstructured":"Dimopoulos M.A.; Oriol A.; Nahi H.; Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016,375(14),1319-1331","journal-title":"N Engl J Med"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1182\/blood-2019-123156","volume":"134","author":"Thura Win Htut D.P.Q.","year":"2019","unstructured":"Thura Win Htut D.P.Q.; Incidence of second primary malignancies and peripheral sensory neuropathy in patients with multiple myeloma receiving daratumumab containing regimen. Blood 2019,134(S1),5550","journal-title":"Blood"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood-2012-06-430645","volume":"120","author":"Bahlis N.J.","year":"2012","unstructured":"Bahlis N.J.; Darwinian evolution and tiding clones in multiple myeloma. Blood 2012,120(5),927-928","journal-title":"Blood"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/ncomms3997","volume":"5","author":"Bolli N.","year":"2014","unstructured":"Bolli N.; Avet-Loiseau H.; Wedge D.C.; Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 2014,5(1),2997","journal-title":"Nat Commun"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1038\/s41375-020-0921-y","volume":"34","author":"Neuse C.J.","year":"2020","unstructured":"Neuse C.J.; Lomas O.C.; Schliemann C.; Genome instability in multiple myeloma. Leukemia 2020,34(11),2887-2897","journal-title":"Leukemia"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1158\/0008-5472.CAN-15-2962","volume":"76","author":"Lloyd M.C.","year":"2016","unstructured":"Lloyd M.C.; Cunningham J.J.; Bui M.M.; Gillies R.J.; Brown J.S.; Gatenby R.A.; Darwinian dynamics of intratumoral heterogeneity: not solely random mutations but also variable environmental selection forces. Cancer Res 2016,76(11),3136-3144","journal-title":"Cancer Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3390\/cancers13020215","volume":"13","author":"Suzuki K.","year":"2021","unstructured":"Suzuki K.; Nishiwaki K.; Yano S.; Treatment strategies considering micro-environment and clonal evolution in multiple myeloma. Cancers 2021,13(2),215","journal-title":"Cancers"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41375-018-0339-y","volume":"33","author":"Dejoie T.","year":"2019","unstructured":"Dejoie T.; Corre J.; Caillon H.; Moreau P.; Attal M.; Loiseau H.A.; Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements. Leukemia 2019,33(2),313-318","journal-title":"Leukemia"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1515\/cclm-2015-0689","volume":"54","author":"Caldini A.","year":"2016","unstructured":"Caldini A.; Nozzoli C.; Terreni A.; New patterns of relapse in multiple myeloma: a case of \u201clight chain escape\u201d in which FLC predicted relapse earlier than urine and serum immunofixation. Clinic Chem Lab Med (CCLM) 2016,54(6),991-995","journal-title":"Clinic Chem Lab Med (CCLM)"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1182\/blood-2013-12-542662","volume":"123","author":"Brioli A.","year":"2014","unstructured":"Brioli A.; Giles H.; Pawlyn C.; Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood 2014,123(22),3414-3419","journal-title":"Blood"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/809840","volume":"2015","author":"Kraj M.","year":"2015","unstructured":"Kraj M.; Kruk B.; Endean K.; Warzocha K.; Budziszewska K.; D\u0105browska M.; Light chain escape in 3 cases: evidence of intraclonal heterogeneity in multiple myeloma from a single institution in Poland. Case Rep Hematol 2015,2015,1-5","journal-title":"Case Rep Hematol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1182\/bloodadvances.2019000731","volume":"3","author":"Sridharan A.","year":"2019","unstructured":"Sridharan A.; Schinke C.D.; Georgiev G.; Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood Adv 2019,3(23),3962-3967","journal-title":"Blood Adv"}],"container-title":["Recent Patents on Anti-Cancer Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574892818666230619093300","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/218054\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574892818666230619093300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T09:14:26Z","timestamp":1704791666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/218054\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574892818666230619093300","relation":{},"ISSN":["1574-8928"],"issn-type":[{"value":"1574-8928","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}